echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > The results of the fourth batch of national elections were officially announced

    The results of the fourth batch of national elections were officially announced

    • Last Update: 2021-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 8, after a four-day publicity period, Shanghai Sunshine Pharmaceutical Procurement Network announced the fourth batch of national harvest officially selected results, meaning that the industry's fourth batch of national harvest curtain, it is expected that the national patients will use the collection in May after the price reduction of drugs.
    , compared with the results of the proposed election, the fourth batch of official announcement results did not change much.
    data show that the fourth batch of 45 varieties included in 80 product regulations, the maximum procurement scale of more than 25 billion yuan, is expected to save 12.4 billion yuan per year in drug costs. the
    collection covers diabetes, hypertension, respiratory diseases, psychotherapy, oncology medication, fungal infections, anaesthetic pain, eye drops and other fields, including 7 national health insurance Class A drugs, 35 Class B drugs, 2 non-medical insurance drugs (ibuprofen injections, injections of bivaldide).
    the highest effective declared price, the average price reduction of the selected drugs 52%, Qilu Pharmaceutical injection of Parexib sodium achieved the highest decline, up to 96%.
    the final results, the participation of the original pharmaceutical companies is still not high.
    the largest number of multinational pharmaceutical companies involved in the product are Novarma, Grigg Ingham, AstraZeneta.
    5 foreign enterprises in china, and only 2 of them are original products.
    starting from the third batch of national mining, the original drug research enterprises running mentality is becoming increasingly obvious, many foreign enterprises quoted higher than the highest effective declared price, equivalent to directly give up the collection market.
    And in the fourth batch of 45 varieties, the original foreign enterprises still maintain a negative attitude, at this time, domestic pharmaceutical companies can be the winning way to jointly split the public hospital drug use cake, accelerate import substitution.
    This can be clearly seen from the results of the bid, domestic pharmaceutical companies actively participate, the domestic leading enterprises become the main force - Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Stone Pharmaceuticals Group, China Biopharmaceuticals and Fosun Pharmaceuticals have 6 varieties of winning bids, Dongsun Pharmaceuticals, Jiangsu Howson and Colum Pharmaceuticals have 4 varieties of winning bids, Jiangsu Hengrui has 3 varieties of winning bids.
    In contrast, the cautious participation of foreign pharmaceutical companies: a total of 20 foreign companies participated in 41 varieties of quotations, the final bid of only 5 varieties, and two of the original research products, respectively, Sanofi's ammonia pills, Fessen Yuscabi's propofol medium / long chain fat emulsion, the quotations are in the first place, priority selection of supply areas.
    2 implementation, the rapid realization of import substitution with the fourth batch of national mining in May officially landed, how much market will be achieved import substitution? Forty-five generic drugs, with total sales of 55 billion yuan at the terminals of public medical institutions in China, 21 of which had sales of more than 1 billion yuan, led by 6.67 billion yuan for pentoazole injections and 5.98 billion yuan for ammonia bromosot injections.
    45 varieties in 2019 sample hospital sales of the top 10 varieties, 9 varieties of the largest production enterprises for foreign pharmaceutical enterprises.
    of 21 collected drugs with sales of more than 1 billion yuan, 20 original drug manufacturers have been approved for import, according to the company's internal network data.
    And in 2019, China's public medical institutions terminal competition pattern, 11 pharmaceutical manufacturers market share of more than 50%, of which the salatan ammonia chloride level I. oral normal release dosage form, sorafini oral normal release dosage form two drugs by the original research manufacturers exclusive market.
    the sales base of these varieties is large, the effect of imitation replacing the original research will be more obvious.
    research institutions believe that in the previous practice of national renewal, has shown that the consistent evaluation of products on the original drug has a strong alternative.
    the original research drug if the loss of national share, will accelerate the layout of the off-site market or off-standard market, channels or further differentiation.
    3 Normalization The General Office of the State Council issued the Opinions on Promoting the Institutionalization of the Normalization of the Purchase of Drug Centralized Bands to Further Clarify the Normalization Mechanism for Drug Collection.
    main highlights include: 1, focus on the basic medical insurance drug catalog of large quantities, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of all kinds of drugs, so that should be harvested.
    priority should be given to the procurement of drugs that have been evaluated for the quality and efficacy of generic drugs (including the same as between) and the same technology (hereinafter referred to as consistency evaluation).
    2, qualified drugs to reach a certain amount or amount, that is, to start centralized belt procurement.
    In this regard, Chen Jinfu, deputy director of the State Health Insurance Administration, made this clear in the relevant briefing: the start of a batch of collection to accumulate a certain amount, referred to as "basket", will not be a variety of tricks, the choice of conditions focused on the medical insurance catalog, clinical necessities, large amount of medication and high amount, thus forming a collection trigger mechanism.
    3, the exploration of adaptive or functional treatment similar, different generic drugs combined collection, biologically similar drugs, including large varieties of Chinese medicine into the collection, which is an institutional requirement, but the rules will be more optimized, more targeted, quality more in line with the properties of the drug itself.
    can be summed up in two sentences: inclusion in the collection is unquestionable, quality must be a priority consideration, the rules must be more in line with market requirements.
    4, promote the construction of regional and national alliance procurement mechanism;
    Fengyun drug talk has been analyzed and calculated, according to the timeline and event logic, the second quarter of 2021 began to the provinces of the country to 500 large catalogs and local large amounts, large sales-based secondary belt volume will soon land, the fifth batch of belt volume picking large probability will be in June as expected.
    , the fourth batch was executed in May, which, in accordance with past practice, means that the fifth batch is not far away.
    with the normalization of national mining, rules and varieties of choice have been touched, it can be seen that pharmaceutical companies can not relax, ready.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.